NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Longfellow95,

"Following revised business plans, application for MHRA/ HTA license will be Q3 2019."

I suppose it should be mentioned that in last years report, the target for licencing was Q2 2018. So we are almost certainly looking at further mothballing.

I imagine that they want to see what finally happens with Brexit, which may lead to two sets of GMP guidelines, parallel licencing regimes, and set up rules regarding requirements for exporting CGT products into Europe.

Just as well we have the right man onboard in respect of the above in Prof Lowdell.

https://www.terrapinn.com/conference/festival-of-biologics-usa/speaker-mark-LOWDELL.stm

And for their 'revised business plans' to come to fruition.

Brexit: "Le Pire" n'est pas impossible! (LOL)